LARGE SCALE GENETIC STUDY FINDS NEW LINK BETWEEN IRRITABLE BOWEL SYNDROME & CARDIOVASCULAR SYSTEM
With
Dr. Leticia Camargo Tavares,
Postdoctoral Scientific Researcher
Hypertension Laboratory,
School of Biological Sciences
Monash University, Clayton, Victoria, Australia
Professor Mauro D’Amato,
Professor of Medical Genetics,
Department of Medicine and Surgery,
LUM University in Casamassima, Italy &
Ikerbasque Research Professor and
Head of the Gastrointestinal Genetics Lab,
CIC bioGUNE, Derio, Spain
CASE STUDY
Filmed in Clayton, Victoria, Australia & Online | May 2025
Research published April 2024 in the journal Cellular and Molecular Gastroenterology and Hepatology sheds light on disease mechanisms common to irritable bowel syndrome (IBS) and cardiovascular diseases (CVD).
Led by Dr Leticia Camargo Tavares, a Postdoctoral Fellow at the Hypertension Research Laboratory within Monash University’s School of Biological Sciences, the study revealed novel insights into the genetic underpinnings of IBS, offering potential avenues for therapeutic intervention.
IBS is one of the most prevalent gastrointestinal disorders globally, affecting up to 10 per cent of the population, with a disproportionate impact on women.
It is characterised by a complex range of symptoms including abdominal pain, bloating, diarrhea and constipation. IBS significantly compromises patients’ quality of life. Despite its widespread prevalence, the cause of IBS remains unclear, thus limiting treatment options.
An international consortium of researchers, drawing expertise from Monash University (Australia), CIC bioGUNE (Spain), LUM University, IRGB-CNR, CEINGE, and the University of Naples Federico II (Italy), as well as the University of Groningen (Netherlands), embarked on a comprehensive investigation.
Analysing data from two large European population cohorts — UK Biobank and Lifelines — the team scrutinised the genetic landscapes of 24,735 people with IBS and 77,149 symptom-free individuals.
Their analysis uncovered four genomic regions, including two previously unidentified loci, associated with increased susceptibility to IBS.
These genetic hotspots implicate pathways central to gastrointestinal motility, intestinal mucosal integrity, and circadian rhythm regulation.
“Although we’re yet to conclusively pinpoint specific genes and mechanisms, these findings provide novel insights into IBS pathophysiology, highlighting potential therapeutic targets. So, we expect follow-up research to build on these discoveries,” Dr Tavares said.
Moreover, the researchers found a link between IBS predisposition and various cardiovascular ailments, encompassing hypertension, ischemic heart disease, and angina pectoris.
Professor Mauro D’Amato, senior author and study supervisor from CIC bioGUNE and LUM University, described this new evidence as the most exciting outcome, underscoring the potential for shared therapeutic modalities.
In another important finding, the study revealed that IBS heritability (the weight of genes in determining one’s risk of disease), might be higher than previously thought. This, the authors say, may stem from their adherence to standardised classification criteria in delineating IBS phenotypes, notably the Rome Criteria from the Rome Foundation.
Source: Adapted from Monash University media release
-
CASE STUDY Role of Exercise in Metabolic Associated Fatty Liver Disease
Dr. Shelley Keating AES AEP* is an Accredited Exercise Physiologist, a researcher, and a senior lecturer at the School of Human Movement and Nutrition Sciences at the University of Queensland in Brisbane, Australia. Dr. Keating’s research primarily focuses on the role of exercise in the management of metabolic dysfunction associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease. MASLD affects a significant portion of the global adult population, with many individuals unaware of their condition.
-
Investigating invasive lobular carcinoma and metaplastic breast cancer sub-types
Assoc Prof McCart Reed is the scientific lead on an MRFF-funded (Medical Research Future Fund) genomics program investigating the potential for the application of Whole Genome Sequencing in the breast cancer care pathway in Australia, ‘Q-IMPROvE’. She applies genomics and spatial transcriptomics methodologies to archival clinical samples to understand the differences between tumour types and their potential for treatment. Amy is passionate about clinical research, biobanking and precision oncology. In addition to her breast cancer research portfolio, she is on the steering committee for the Brisbane Breast Bank and the Scientific Advisory Board for Breast Cancer Trials.
-
Leukaemia microenvironment & high risk childhood leukaemia
Associate Professor Laurence Cheung is now an Associate Professor at the Curtin Medical School as well as Curtin Medical Research Institute, and a Co-head of the Leukaemia Translational Research Laboratory at The Kids.
He has attracted over $8.7 million in research funding, including 16 awards as CIA (over $6.1 million). Assoc Prof Cheung was named the 2019 Cancer Council of WA Early Career Cancer Researcher of the Year and received the STEM Early Career Research Award at Curtin University in 2019.
